Acadia Pharmaceuticals (ACAD) Change in Accured Expenses (2010 - 2026)

Acadia Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$6.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 440.85% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$27.7 million (down 418.43% YoY), while the FY2025 annual figure was -$19.3 million, down 762.26% from the prior year.
• Change in Accured Expenses was -$6.5 million for Q1 2026 at Acadia Pharmaceuticals, up from -$15.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $54.9 million in Q3 2023 to a low of -$49.0 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged -$867235.3 across 5 years, with a median of -$3.8 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses soared 688.34% in 2025, then tumbled 440.85% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at -$15.7 million in 2022, then plunged by 211.26% to -$49.0 million in 2023, then rose by 23.67% to -$37.4 million in 2024, then jumped by 59.61% to -$15.1 million in 2025, then jumped by 56.95% to -$6.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.5 million (Q1 2026), -$15.1 million (Q4 2025), and -$14.7 million (Q3 2025), per Business Quant data.